Clinical Trial Update: CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment [Phase 1, Phase 2]

View source ↗

Summary

A early-phase clinical trial investigating CD19 CAR-T cells and CD19-positive feeder T cells as consolidation therapy for acute lymphoblastic leukemia in remiss…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia in Remission

Drugs mentioned

• CD19 Chimeric Antigen Receptors (CD19 CAR-T)
• CD19-positive feeder T cells (CD19+ feeder T cells)

Snippet

Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Conditions: Acute Lymphoblastic Leukemia in Remission | Phase 1, Phase 2 | Status: UNKNOWN